Akeso: HARMONi-3 trial adds OS analysis, Summit launches ATM financing, maintains positive rating (J.P. Morgan)
In its quarterly report, Akeso's American partner Summit updated the global OS analysis plan for the third phase of HARMONi-3 and filed for a new ATM financing of up to US$380 million.
In its quarterly report, Akeso's American partner Summit updated the global OS analysis plan for the third phase of HARMONi-3 and filed for a new ATM financing of up to US$380 million. Among them, the PFS analysis of the squamous cohort has been extended to 2H26, and a second OS interim look of 1H27 has been added; the PFS analysis of the non-squamous cohort is expected to be in 1H27. The financing will cover part of the funding gap for the ivonescimab trial. Although the financing plan may bring short-term dilution concerns, Summit's cash has increased to approximately US$690 million, and Akeso's overseas commercialization constitutes its main future revenue path. The market had previously been uncertain about the data readout schedule of HARMONi-3, and this update clarified the key nodes. It is highlights to pay attention to the subsequent OS data release and FDA review progress. One-sentence conclusion: The financing plan of Akeso’s partner Summit brings short-term uncertainty, but the clarification of the key trial time of HARMONi-3 paves the way for medium-term value realization. Positive/negative: Positive for Akeso (9926.HK). The current share price has partially priced in the dilution risk from the financing, but an updated readout schedule for key clinical data has provided a positive catalyst for the valuation. Catalysts: 1) Interim readout of OS data from the HARMONi-3 trial (2027); 2) FDA review progress of ivonescimab; 3) Summit’s financing progress and Akeso’s overseas commercialization milestones.